An exploration of the experience of dapagliflozin in clinical practice

Despite the availability of established treatments, heart failure (HF) is associated with a poor prognosis and suboptimal management, highlighting the need for new treatment and prevention options. It is suggested that sodium-glucose cotransporters 2 inhibitors can provide a beneficial therapeutic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Anitha, Anuba Paulvarnan, Balasubramanian, Swetha, Ramalingam, Arun Gopal, Samuel Kennady, Shini Rubina, Ganamurali, Nila, Dhanasekaran, Dhivya, Sabarathinam, Sarvesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704035/
https://www.ncbi.nlm.nih.gov/pubmed/36457541
http://dx.doi.org/10.2144/fsoa-2022-0038
_version_ 1784839976011169792
author Anitha, Anuba Paulvarnan
Balasubramanian, Swetha
Ramalingam, Arun Gopal
Samuel Kennady, Shini Rubina
Ganamurali, Nila
Dhanasekaran, Dhivya
Sabarathinam, Sarvesh
author_facet Anitha, Anuba Paulvarnan
Balasubramanian, Swetha
Ramalingam, Arun Gopal
Samuel Kennady, Shini Rubina
Ganamurali, Nila
Dhanasekaran, Dhivya
Sabarathinam, Sarvesh
author_sort Anitha, Anuba Paulvarnan
collection PubMed
description Despite the availability of established treatments, heart failure (HF) is associated with a poor prognosis and suboptimal management, highlighting the need for new treatment and prevention options. It is suggested that sodium-glucose cotransporters 2 inhibitors can provide a beneficial therapeutic approach to significantly lower the disease burden associated with cardiovascular illness in both patients with and without Type 2 diabetes mellitus. This review focuses on the therapeutic aspects of dapagliflozin in clinical practice. Future studies may intend to confirm the significant clinical benefits of sodium-glucose cotransporter-2 inhibitors.
format Online
Article
Text
id pubmed-9704035
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Future Science Ltd
record_format MEDLINE/PubMed
spelling pubmed-97040352022-11-30 An exploration of the experience of dapagliflozin in clinical practice Anitha, Anuba Paulvarnan Balasubramanian, Swetha Ramalingam, Arun Gopal Samuel Kennady, Shini Rubina Ganamurali, Nila Dhanasekaran, Dhivya Sabarathinam, Sarvesh Future Sci OA Commentary Despite the availability of established treatments, heart failure (HF) is associated with a poor prognosis and suboptimal management, highlighting the need for new treatment and prevention options. It is suggested that sodium-glucose cotransporters 2 inhibitors can provide a beneficial therapeutic approach to significantly lower the disease burden associated with cardiovascular illness in both patients with and without Type 2 diabetes mellitus. This review focuses on the therapeutic aspects of dapagliflozin in clinical practice. Future studies may intend to confirm the significant clinical benefits of sodium-glucose cotransporter-2 inhibitors. Future Science Ltd 2022-11-01 /pmc/articles/PMC9704035/ /pubmed/36457541 http://dx.doi.org/10.2144/fsoa-2022-0038 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Commentary
Anitha, Anuba Paulvarnan
Balasubramanian, Swetha
Ramalingam, Arun Gopal
Samuel Kennady, Shini Rubina
Ganamurali, Nila
Dhanasekaran, Dhivya
Sabarathinam, Sarvesh
An exploration of the experience of dapagliflozin in clinical practice
title An exploration of the experience of dapagliflozin in clinical practice
title_full An exploration of the experience of dapagliflozin in clinical practice
title_fullStr An exploration of the experience of dapagliflozin in clinical practice
title_full_unstemmed An exploration of the experience of dapagliflozin in clinical practice
title_short An exploration of the experience of dapagliflozin in clinical practice
title_sort exploration of the experience of dapagliflozin in clinical practice
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704035/
https://www.ncbi.nlm.nih.gov/pubmed/36457541
http://dx.doi.org/10.2144/fsoa-2022-0038
work_keys_str_mv AT anithaanubapaulvarnan anexplorationoftheexperienceofdapagliflozininclinicalpractice
AT balasubramanianswetha anexplorationoftheexperienceofdapagliflozininclinicalpractice
AT ramalingamarungopal anexplorationoftheexperienceofdapagliflozininclinicalpractice
AT samuelkennadyshinirubina anexplorationoftheexperienceofdapagliflozininclinicalpractice
AT ganamuralinila anexplorationoftheexperienceofdapagliflozininclinicalpractice
AT dhanasekarandhivya anexplorationoftheexperienceofdapagliflozininclinicalpractice
AT sabarathinamsarvesh anexplorationoftheexperienceofdapagliflozininclinicalpractice
AT anithaanubapaulvarnan explorationoftheexperienceofdapagliflozininclinicalpractice
AT balasubramanianswetha explorationoftheexperienceofdapagliflozininclinicalpractice
AT ramalingamarungopal explorationoftheexperienceofdapagliflozininclinicalpractice
AT samuelkennadyshinirubina explorationoftheexperienceofdapagliflozininclinicalpractice
AT ganamuralinila explorationoftheexperienceofdapagliflozininclinicalpractice
AT dhanasekarandhivya explorationoftheexperienceofdapagliflozininclinicalpractice
AT sabarathinamsarvesh explorationoftheexperienceofdapagliflozininclinicalpractice

Ejemplares similares